Shares of Helix Biopharma Corp. (OTCMKTS:HBPCF – Get Free Report) were down 55.5% during trading on Monday. The company traded as low as $0.77 and last traded at $0.77. 200 shares traded hands during mid-day trading, The stock had previously closed at $1.73.
Helix Biopharma Stock Performance
The stock has a market capitalization of $58.81 million, a P/E ratio of -19.25 and a beta of 0.18. The company has a fifty day simple moving average of $1.67 and a two-hundred day simple moving average of $1.70.
About Helix Biopharma
Helix BioPharma Corp. is a Canadian biotechnology company focused on developing novel therapies for cancer. Its research has centered on targeted treatments intended to address the tumor microenvironment and improve the delivery or effectiveness of anticancer agents.
The company’s principal investigational product has been L-DOS47, an antibody-enzyme conjugate designed to target CEACAM6, a protein expressed on the surface of certain cancer cells. The treatment is intended to alter the acidic conditions surrounding tumors, which may help create an environment less favorable to cancer-cell growth.
Featured Articles
- Five stocks we like better than Helix Biopharma
- Can Boxabl Turn Modular Homes Into AI Data Center Infrastructure?
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
- 4 Stocks That Could Split Next—and Why Investors Are Watching
- Oura’s IPO Freeze Isn’t the Warning Sign It Looks Like
Receive News & Ratings for Helix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Helix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
